Treatment of malignant pleural effusion is a complicated algorithm which depends on the longevity of the patient, the cell type and the primary cancer, the control of the tumor in the rest of the body, symptomatic benefit from therapeutic thoracentesis, and other comorbidities including general debility and COPD.